Topical Pharmaceutical Formulation Stabilizing Ester Compounds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Compounds with ester groups, such as those represented by Formula I, are prone to hydrolysis in nucleophilic environments, leading to instability in conventional topical pharmaceutical compositions, which are not suitable for maintaining structural integrity and therapeutic efficacy in treating cancer or pre-cancerous conditions.
Innovation Solution
The development of novel topical pharmaceutical compositions using specific non-polar excipients like glycol diesters, triglycerides, and aprotic organic solvents, which are compatible with the lipophilic nature of Compound I, ensuring stability and chemical compatibility, thereby forming stable formulations for effective topical administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional topical excipients are used in compositions containing Compound I, then the composition can be formulated for topical administration, but the ester group of Compound I undergoes hydrolysis leading to degradation and loss of therapeutic efficacy
Solution Approach 1:
The patent removes water and nucleophilic excipients from the formulation that would cause hydrolysis of the ester group. By extracting the harmful nucleophilic components and replacing them with non-nucleophilic alternatives, the composition maintains both manufacturability and chemical stability of Compound I
Solution Approach 2:
The patent changes the chemical parameters of the excipients from nucleophilic to non-nucleophilic character. By selecting excipients with specific chemical properties (non-nucleophilic, aprotic), the formulation achieves compatibility with the ester-containing Compound I while maintaining topical applicability
2Stability of the object's composition
If non-polar excipients are used to stabilize Compound I, then chemical compatibility and stability are improved, but the formulation complexity increases
Solution Approach 1:
The patent employs non-polar excipients that serve multiple functions simultaneously: they act as solvents for the lipophilic Compound I, provide chemical stability by preventing hydrolysis, and maintain topical applicability. This multi-functionality reduces the need for additional stabilizing agents, thereby managing formulation complexity
3Object-affected harmful factors
If hydroxyl-containing excipients are used in the composition, then the formulation can provide moisturizing benefits, but they act as nucleophiles and cause degradation of the ester group in Compound I
Solution Approach 1:
The patent addresses the dual nature of hydroxyl-containing excipients by eliminating the harmful nucleophilic aspect while preserving the beneficial moisturizing effect through alternative means. Non-nucleophilic excipients are selected that do not degrade the ester group, thereby converting the potential harm into a safe formulation approach
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of these excipients in the compositions provides a stable and effective delivery of Compound I, enhancing its therapeutic benefit for treating or preventing cancer, pre-cancerous conditions, and benign hyperproliferative disorders, including actinic keratosis, by maintaining the compound's integrity and bioavailability.
Implementation Method 1
Compounds comprising an ester group are prone to hydrolysis, which constitutes an obstacle in the preparation of a suitable formulation which maintains the structural integrity of the active compound
Implementation Method 2
These excipients are devoid of hydroxyl (OH) or other nucleophilic functionalities, and are mainly non-polar compounds that are compatible with the lipophilic nature of Compound I
Data Source
AI summary
The present invention relates to novel pharmaceutical compositions for topical administration of a compound Formula I and methods of treating or preventing cancer or pre-cancerous conditions or benign hyperproliferative disorders, by administering the composition to a subject in need thereof. In particular, the present invention provides a stable formulation of active a compound of Formula I useful for the treatment of disorders such as actinic keratosis.